Credent Connect N Care (NSE: CREDENT) and Molbio Diagnostics Limited (NSE: MOLBIO) are both listed in the Medical Testing, Analyzing, and Diagnostic Equipment industry. Credent Connect N Care has a market capitalisation of ₹728 Cr and Molbio Diagnostics ₹15,144 Cr, as of 9 Nov 2026. Their P/E ratios are 28.6 and 89 respectively.
| Metric | Credent Connect N Care | Molbio Diagnostics |
|---|---|---|
| NSE Symbol | CREDENT | MOLBIO |
| BSE Code | — | 544866 |
| Share Price | ₹399.50 | ₹1,333.80 |
| Market Cap | ₹728 Cr | ₹15,144 Cr |
| P/E Ratio | 28.6 | 89 |
| Return on Assets | 28.93% | 9.24% |
| Beta (1Y) | 2.33 | -0.17 |
| 52-Week Range | ₹383.05 – ₹402.00 | ₹926.35 – ₹1,686.80 |
| Latest Quarter | — | Q2 FY27 |
| Quarterly Revenue | — | ₹259 Cr |
| Quarterly Net Profit | — | ₹8 Cr |
| Net Margin | — | 3.0% |
| Results Basis | — | consolidated |
| Headquarters | New Delhi, Delhi | Verna, Goa |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Credent Connect N Care Limited operates as a healthcare services provider engaged in delivering integrated logistics, workforce solutions, and technology-enabled support to healthcare institutions in India. The company provides comprehensive operational and logistics services to diagnostic laboratories, In Vitro Diagnostics (IVD) companies, pharmaceutical companies, clinics, and other healthcare enterprises. Its services include home sample collection through trained phlebotomists; Operations & Supply Chain Services through stationed phlebotomy teams at laboratories and hospitals; deployment o…
Molbio Diagnostics Limited, a point-of-care diagnostics company, provides healthcare technologies to diagnose infectious and non-communicable diseases. It manufactures and sells chip based diagnostic devices, chips and reagents, X-ray equipment's, and single/dual detectors. It also offers disposable POCT devices, which includes dengue, malaria, and COVID-19 tests; Tabletop analysers, a portable machine that are used to perform molecular or immunodiagnostic tests to detect infectious diseases, such as tuberculosis, human papillomavrus, STIs, and GI disorders. In addition, the company offers Tru…
Molbio Diagnostics has a market capitalisation of ₹15,144 Cr, against ₹728 Cr for Credent Connect N Care as of 9 Nov 2026, about 20.8 times the size by market cap.
Credent Connect N Care has a P/E of 28.6 and Molbio Diagnostics a P/E of 89 as of 9 Nov 2026.
Both are classified under Health Care Equipment and Supplies > Health Care Equipment > Medical Testing, Analyzing, and Diagnostic Equipment on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.